Aenitis Technologies

Executive Summary

Aenitis Technologies is a French biotech company pioneering a modular, GMP-ready platform for bioprocessing based on patented acoustic levitation technology. Founded in 2016 as a spin-off from CNRS and ESPCI Paris, the company's contact-free cell handling devices and consumables enable gentle sorting, washing, isolation, and concentration of cells. This technology addresses critical bottlenecks in the manufacturing of advanced therapies, such as cell and gene therapies, by improving scalability, efficiency, and product quality. By eliminating physical contact and shear stress, Aenitis aims to enhance cell viability and reduce contamination risks, offering a transformative solution for the rapidly growing cell therapy market. Aenitis operates in a high-demand sector where current manufacturing processes are often manual, inefficient, and difficult to scale. The company's platform has the potential to become a standard in bioprocessing, providing a sterile, automated, and reproducible method for cell handling. With the global cell and gene therapy market expected to exceed $30 billion by 2030, Aenitis is well-positioned to capture value through equipment sales, consumables, and licensing. The company's technology has received approval from regulatory bodies, indicating readiness for commercialization. Key milestones ahead include securing strategic partnerships with therapy developers and expanding its product portfolio to address additional applications in diagnostics and research.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a top-10 cell therapy developer60% success
• Q2 2026Completion of Series B financing round to scale production75% success
• Q2 2027CE marking or FDA 510(k) clearance for the core cell manipulation device50% success